Monica Bertagnolli, President Biden’s nominee to lead the National Institutes of Health, spent her confirmation hearing Wednesday stuck in the middle of Republicans’ and Democrats’ bickering over her agency’s role in high drug costs, ultimately refusing to commit to either party’s approach.
Bertagnolli similarly walked a line on government funding for gender-affirming care research and other hotly politicized health care issues, though she did stress that transgender youth are some of the country’s most vulnerable people.
The long-awaited hearing came months after Committee Chairman Bernie Sanders (I-Vt.) pledged to stall her confirmation process until Biden did more to address high drug prices, like an assurance that the NIH would insert reasonable pricing requirements into deals with commercial drugmakers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect